Get started
Author

Ying Ji Buechler

Observed names: Y Buechler, Y J Buechler, Y. Buechler, Y. Ji-Buechler, Y.J. Buechler, Ying Buechler, Ying J. Buechler, Ying Ji-Buechler, Ying Ji-buechler, Ying Ji‐Buechler, Yingji Buechler
ORCID: 0009-0002-3117-0929
Observed ORCID: 0009-0002-3117-0929
OpenAlex ID: A5026631878
Fluorescence ratio imaging of cyclic AMP in single cells
1991 · Stephen R. Adams, Alec T. Harootunian, et al. · Nature · 706
Optimized clinical performance of growth hormone with an expanded genetic code
2011 · Ho Cho, Tom Daniel, et al. · Proceedings of the National Academy of Sciences · 204
Targeting DNA to Cells with Basic Fibroblast Growth Factor (FGF2)
1996 · Barbara A. Sosnowski, Ana Maria Gonzalez, et al. · Journal of Biological Chemistry · 149
PDF
In vivo inhibition of lens regrowth by fibroblast growth factor 2-saporin.
1995 · F F Behar-Cohen, T David, et al. · PubMed · 59
Interaction of the Regulatory and Catalytic Subunits of cAMP-dependent Protein Kinase
1997 · Robin M. Gibson, Ying Ji-Buechler, et al. · Journal of Biological Chemistry · 54
Regulation-defective mutants of type I cAMP-dependent protein kinase. Consequences of replacing arginine 94 and arginine 95
1993 · Y.J. Buechler, F.W. Herberg, et al. · Journal of Biological Chemistry · 54
Mutations in the autoinhibitor site of the regulatory subunit of cAMP-dependent protein kinase I. Replacement of Ala-97 and Ser-99 interferes with reassociation with the catalytic subunit
1991 · Y J Buechler, S S Taylor · Journal of Biological Chemistry · 33
Cytotoxic effects of FGF2-saporin on bovine epithelial lens cells in vitro.
1995 · F F Behar-Cohen, T David, et al. · PubMed · 26
Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2024 · Lillian K. Skidmore, David Mills, et al. · Molecular Cancer Therapeutics · 24
PDF
Effects of Recombinant Human Interleukin 11 on Thrombocytopenia and Neutropenia in Irradiated Rhesus Monkeys
2004 · Jing Hao, Liansheng Sun, et al. · Radiation Research · 23
Identification of electrostatic interaction sites between the regulatory and catalytic subunits of cyclic AMP‐dependent protein kinase
1997 · Robin M. Gibson, Ying Ji‐Buechler, et al. · Protein Science · 21
Analytical comparability to evaluate impact of manufacturing changes of ARX788, an Anti-HER2 ADC in late-stage clinical development
2023 · Wayne Yu, Mysore Ramprasad, et al. · PLoS ONE · 11
PDF
Single‐stage chromatographic clarification of Chinese Hamster Ovary cell harvest reduces cost of protein production
2023 · Brian O'Mara, Naveen Kumar Singh, et al. · Biotechnology Progress · 10
PDF
Abstract 3997: Preclinical characterization of ARX517, a next-generation anti-PSMA antibody drug conjugate for the treatment of metastatic castration-resistant prostate cancer
2023 · Lillian Skidmore, David Mills, et al. · Cancer Research · 5
Synthesis and Characterization of a Homogeneous Chemical Conjugate Between Basic Fibroblast Growth Factor and Saporin
1995 · Ying Ji Buechler, Barbara A. Sosnowski, et al. · European Journal of Biochemistry · 5
PDF
Abstract 5616: Tumor-targeted immune activation via a site-specific TLR7-agonist antibody-drug conjugate
2022 · Mingchao Kang, Sung-Ju Moon, et al. · Cancer Research · 4
41P Evaluation of ARX517: A next-generation anti-PSMA antibody drug conjugate for prostate cancer treatment, in preclinical enzalutamide-resistant and enzalutamide-sensitive pharmacology models and in toxicology models
2023 · S. Zhang, D. Mills, et al. · Annals of Oncology · 3
PDF
Abstract 6352: Preclinical discovery of ARX622: A site-specific, TLR7 agonist, HER2-targeted immune-stimulatory antibody drug conjugate for treatment of multiple solid tumor types
2024 · David Mills, Ji Young Kim, et al. · Cancer Research · 1
Data from Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2024 · Lillian K. Skidmore, David Mills, et al.
Table S1 from Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer
2024 · Lillian K. Skidmore, David Mills, et al.
Author response for "Single‐stage chromatographic clarification of CHO cell harvest reduces cost of protein production"
2022 · Brian O'Mara, Naveen Kumar Singh, et al. · Publons reviews and discussion
Abstract CT211: A phase 1 dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, and anti- tumor activity of ARX517 in subjects with advanced solid tumors resistant or refractory to standard therapies (APEX-01 trial, NCT04662580)
2022 · Russell K. Pachynski, Luke Nordquist, et al. · Cancer Research
Process optimization, manufacturing changes from early to late phase development, and comparability of Resolaris
2018 · Ying Buechler, Darin Lee, et al.
Protein Kinase Structure & Function: cAMP-Dependent Protein Kinase
1991 · S. S. Taylor, W. Yonemoto, et al. · Springer eBooks
Works count: 25
Citation count: 1,392
H-index: 11
I10-index: 13
Year
Topic
Type